Email this article Comparative efficacy of lotensin vs Capoten in patients with chronic cardiac failure
- Authors: Zodionchenko VS1, Timofeeva NY.1, Li VV1, Suvorova SS1
-
Affiliations:
- Issue: Vol 78, No 4 (2003)
- Pages: 54-58
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29364
- ID: 29364
Cite item
Full Text
Abstract
Aim. To compare clinical response to captopril (capoten) vs benazepril (lotensin) in patients with chronic cardiac failure (CCF) as well as their influence on central hemodynamics, some indices of platelet hemostasis, myocardial ischemia degree, exercise tolerance.
Material and methods. 54 patients with CCF (NYHA FC II and III) entered the trial. 26 patients received captopril (capoten) in a dose 25-75 mg/day (group 1) while 28patients were given benazepril (lotensin) in a dose 5-30 mg/day for 4 weeks (group 2). Group II was treated for the following 24 weeks. The results were assessed with electro- and echocardiography, bicycle exercise test, platelet aggregation measurement and by clinical symptoms.
Results. A positive clinical response was registered to both the drugs which improved the functional class, exercise tolerance, platelet aggregation, reduced the number of arrhythmia and myocardial ischemia episodes. Long-term treatment with lotensin resulted in further improvement of clinical and laboratory indices. Side effects, in which lotensin discontinuation is needed, were absent. Lotensin was more potent than capoten in reducing episodes of ST epression on ECG and episodes of painless myocardial ischemia.
Material and methods. 54 patients with CCF (NYHA FC II and III) entered the trial. 26 patients received captopril (capoten) in a dose 25-75 mg/day (group 1) while 28patients were given benazepril (lotensin) in a dose 5-30 mg/day for 4 weeks (group 2). Group II was treated for the following 24 weeks. The results were assessed with electro- and echocardiography, bicycle exercise test, platelet aggregation measurement and by clinical symptoms.
Results. A positive clinical response was registered to both the drugs which improved the functional class, exercise tolerance, platelet aggregation, reduced the number of arrhythmia and myocardial ischemia episodes. Long-term treatment with lotensin resulted in further improvement of clinical and laboratory indices. Side effects, in which lotensin discontinuation is needed, were absent. Lotensin was more potent than capoten in reducing episodes of ST epression on ECG and episodes of painless myocardial ischemia.
Keywords
References
- Современные подходы к диагностике и лечению хронической сердечной недостаточности (изложение Рекомендаций Американской коллегии кардиологов и Американской ассоциации Сердца 2001 г.). Кардиология 2002; 6: 65-78.
- Parker M., Cohn J. N. Consensus recommendations for the management of chronic heart failure. Am. J. Cardiol. 1999; 83: 1A-38A.
- Беленков Ю. Н. Современные подходы к лечению ХСН. Сердеч. недостаточность 2001; 1 (1); 6-8.
- Мареев В. Ю. Результаты наиболее интересных исследований по проблеме сердечной недостаточности в 1999 г. Там же 2000; 1 (1): 8-17.
- Pfeffer M., Braunwald Е., Моуе L. et al. Effect of captopril on mortality in patient with left ventricular dysfunction after myocardial infarction. Results of SAVE trial. N. Engl. J. Med. 1992; 327 (10): 669-677.
- Harry Т., Colfer M. D. et al. Effect of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am. J. Cardiol. 1992; 70: 354-358.
- Maucini G. B. J., Henry G. S., Macaya E. et al. ACE inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 94: 258-265.
- Myers J., Gullstad L. The role of exercise and gas exchange measurements in the prognostic assessment of the patients with heart failure. Curr. Opin. Cardiol. 1998; 13: 145-155.
- Britten M. В., Zeiher A. M. et al. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J. Intern. Med. 1999; 245: 315-327.
Supplementary files
